On Wednesday, Shares of DryShips Inc. (NASDAQ:DRYS), lost -4.29% to $0.555.
DryShips Inc., declared that further to its previous press release dated March 31, 2015, entities controlled by the Company’s Chairman and Chief Executive Officer, George Economou, have exercised their unconditional acceptance to acquire the Company’s six Aframax tankers, Belmar, Calida, Alicante, Mareta, Saga and Daytona.
DryShips Inc. provides ocean transportation services for drybulk and petroleum cargoes, and offshore deepwater drilling services. The company operates through Drybulk, Tanker, and Drilling segments.
Shares of Linn Energy LLC (NASDAQ:LINE), declined -3.35% to $7.78, during its last trading session.
LINN Energy, declared that LINN has signed a definitive agreement to sell its remaining position in Howard County in the Permian Basin for a contract price of $281 million. The transaction is predictable to close in the third quarter 2015 with an effective date of May 1, 2015.
The properties sold comprise about 6,400 net acres prospective for horizontal Wolfcamp drilling and about 2.0 MBoe/d of current production from 133 gross wells.
Linn Energy, LLC, an independent oil and natural gas company, acquires and develops oil and natural gas properties in the Unites States. Its properties are located in the Rockies, the Hugoton Basin, California, east Texas and north Louisiana, the Mid-Continent, the Permian Basin, Michigan/Illinois, and south Texas.
At the end of Wednesday’s trade, Shares of Bank of New York Mellon Corp (NYSE:BK), gained 0.33% to $42.67.
BNY Mellon, has extended its relationship with Raymond James & Associates, Inc. to provide sub-accounting services for more than $140 billion in assets and 6.4 million active investor positions.
BNY Mellon has been providing sub-accounting services to Raymond James since 2009 and also provides custody, credit and treasury services to the company.
The Bank of New York Mellon Corporation, an investment company, provides financial products and services to institutions, corporations, and high net worth individuals in the United States and internationally.
Finally, Exelixis, Inc. (NASDAQ:EXEL), ended its last trade with -3.17% loss, and closed at $3.66.
Exelixis, Inc., declared the appointment of Christopher J. Senner as Executive Vice President and Chief Financial Officer. Mr. Senner has nearly 25 years of experience in biopharmaceutical finance, counting deep expertise in global financial operations and controls, planned planning and analysis, supply chain finance and business development. He joins Exelixis after five years at Gilead Sciences, where he served as Vice President, Corporate Finance. He formerly spent eighteen years at Wyeth in a variety of financial roles with increasing responsibility for many of the company’s divisions and regions. He joins Exelixis in advance of several potentially transformational milestones anticipated this year, counting top-line results from the METEOR phase 3 pivotal trial and the potential U.S. and EU regulatory approvals of cobimetinib, a compound discovered by Exelixis and then licensed to Genentech for further development and commercialization.
In this role, Mr. Senner will oversee the company’s global finance function, leveraging extensive experience gained earlier in his career. While at Gilead, he was accountable for controllership and operational financial planning and analysis, counting research and development, manufacturing, commercial operations, and tax and treasury planning. At Wyeth, he served in a variety of capacities, most notably as CFO of the company’s $10 billion U.S. pharmaceuticals business and the BioPharma Business Unit, a $5 billion global inflammation, oncology and hematology business.
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
